What is Cepham Life Sciences?
Cepham Life Sciences operates as a critical infrastructure provider for the life sciences industry, specializing in the development and distribution of essential research reagents and laboratory supplies. Their product portfolio is anchored in high-precision tools for proteomics, molecular biology, and immunohistochemistry, including specialized ELISA kits and antibodies. By maintaining rigorous ISO 9001:2015 standards, the company has established itself as a reliable partner for research institutions and diagnostic laboratories. Their market position is defined by a commitment to supporting complex scientific workflows, ensuring that researchers have access to the high-fidelity materials required for breakthrough discoveries in biotechnology and clinical diagnostics.
How much funding has Cepham Life Sciences raised?
Cepham Life Sciences has raised a total of $35K across 1 funding round:
Debt
$35K
Debt (2021): $35K with participation from PPP
Key Investors in Cepham Life Sciences
PPP
Public-Private Partnership
What's next for Cepham Life Sciences?
With the recent infusion of capital, Cepham Life Sciences is poised to accelerate its growth trajectory through enhanced product development and expanded market reach. The company is expected to leverage these resources to optimize its supply chain and broaden its catalog of diagnostic tools, catering to the increasing demand for standardized research materials. As the firm transitions through this significant Series B/C stage, the focus will likely shift toward scaling its international distribution network and investing in R&D to maintain its competitive edge in the rapidly evolving life sciences landscape. This strategic expansion will be instrumental in solidifying their role as a foundational supplier for the global scientific community.
See full Cepham Life Sciences company page
